Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours.
Acromegaly
NETs
Neuroendocrine tumours
SRL
Somatostatin receptor ligand
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
21
06
2023
accepted:
25
07
2023
medline:
14
9
2023
pubmed:
13
8
2023
entrez:
12
8
2023
Statut:
ppublish
Résumé
People living with acromegaly and neuroendocrine tumours (NETs) may be treated with injectable somatostatin receptor ligands (SRLs), administered by either a caregiver or as self-injection via a proprietary or generic device. Injection device attributes that contribute to ease of use and storage, minimise preparation requirements, and reduce injection pain are associated with improved adherence and more favourable therapeutic outcomes. The aim of this study was to assess current opinion surrounding favourable SRL device attributes for people living with acromegaly and NETs as well as that of their caregivers. Participants (healthcare professionals [HCPs] and patients/non-HCP caregivers) from 11 countries were invited to answer survey questions related to their demographic, experience, and preferences as they relate to the real-world use of injectable SRL devices. Questions were developed based on review of available literature and meetings with a Scientific Committee. Device attributes preferred by the patient/non-HCP caregiver group (n = 211) included confidence that the correct drug amount is delivered (76%), quick administration with minimal pain/discomfort (68%), and device safety (needle-safety and low risk of contamination; 53%). Device attributes preferred by HCPs (n = 52) were quick administration with minimal pain/discomfort (69%), correct use is easy to learn, confidence in handling the device (63%), and confidence that the correct drug amount is delivered (62%). The results identified key features of injection devices for SRL therapy which merit consideration for optimal management and underscore the importance of patient partnership in treatment decisions.
Identifiants
pubmed: 37573277
doi: 10.1007/s12325-023-02627-6
pii: 10.1007/s12325-023-02627-6
doi:
Substances chimiques
Somatostatin
51110-01-1
Receptors, Somatostatin
0
Ligands
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
4675-4688Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.
Références
Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10:804–26.
doi: 10.1016/S2213-8587(22)00244-3
pubmed: 36209758
O’Toole D, Kunz PL, Webb SM, et al. PRESTO 2: an international survey to evaluate patients’ injection experiences with the latest devices/formulations of long-acting somatostatin analog therapies for neuroendocrine tumors or acromegaly. Adv Ther. 2023;40:671–90.
doi: 10.1007/s12325-022-02360-6
pubmed: 36502449
Raimer-Hall D, Shea HC. Evolution of growth hormone devices: matching devices with patients. Pediatr Nurs. 2015;41:72–7.
pubmed: 26292454
Gau M, Takasawa K. Initial patient choice of a growth hormone device improves child and adolescent adherence to and therapeutic effects of growth hormone replacement therapy. J Pediatr Endocrinol Metab. 2017;30:989–93.
doi: 10.1515/jpem-2017-0146
pubmed: 28771439
Rohrer TR, Horikawa R, Kappelgaard AM. Growth hormone delivery devices: current features and potential for enhanced treatment adherence. Expert Opin Drug Deliv. 2017;14:1253–64.
doi: 10.1080/17425247.2017.1243526
pubmed: 27718757
Chang HJ, Huang K, Wu C. Determination of sample size in using central limit theorem for Weibull distribution. Int J Inf Manag Sci. 2006;17:153–247.
Adelman DT, Burgess A, Davies PR. Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study. Med Devices (Auckl). 2012;5:103–9.
pubmed: 23293542
Ryan P, Phan AT, Adelman DT, Iwasaki M. Neuroendocrine tumors and lanreotide depot: clinical considerations and nurse and patient preferences. Clin J Oncol Nurs. 2016;20:E139–46.
doi: 10.1188/16.CJON.E139-E146
pubmed: 27857269
Strasburger CJ, Karavitaki N, Störmann S, et al. Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur J Endocrinol. 2016;174:355–62.
doi: 10.1530/EJE-15-1042
pubmed: 26744896
pmcid: 4722610
Adelman DT, Van Genechten D, Megret CM, Truong Thanh XT, Hand P, Martin WA. Co-creation of a lanreotide autogel/depot syringe for the treatment of acromegaly and neuroendocrine tumours through collaborative human factor studies. Adv Ther. 2019;36:3409–23.
doi: 10.1007/s12325-019-01112-3
pubmed: 31612358
pmcid: 6860467
Adelman D, Truong Thanh XM, Feuilly M, Houchard A, Cella D. Evaluation of nurse preferences between the lanreotide autogel new syringe and the octreotide long-acting release syringe: an international simulated-use study (PRESTO). Adv Ther. 2020;37:1608–19.
doi: 10.1007/s12325-020-01255-8
pubmed: 32157626
pmcid: 7140743
Darden C, Price M, Ray D, et al. Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors. J Patient Rep Outcomes. 2021;5:82.
doi: 10.1186/s41687-021-00355-5
pubmed: 34491454
pmcid: 8423948
Delemer B, Nguyen-Tan-Hon T, Coriat R, et al. Evaluation of Nurses’ and patients’ overall satisfaction with new and previous formulations of octreotide long-acting release (Sandostatin LAR®): a French observational study. Adv Ther. 2020;37:3901–15.
doi: 10.1007/s12325-020-01429-4
pubmed: 32683667
Cella D, Evans J, Feuilly M, et al. Patient and healthcare provider perspectives of first-generation somatostatin analogs in the management of neuroendocrine tumors and acromegaly: a systematic literature review. Adv Ther. 2021;38:969–93.
doi: 10.1007/s12325-020-01600-x
pubmed: 33432541
pmcid: 7799425
Boguszewski CL, Korbonits M, Artignan A, et al. Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review. Endocrine. 2023;79:527–36.
doi: 10.1007/s12020-022-03227-0
pubmed: 36369434
Hernando J, Kolarova T, Verslype C, et al. HomeLAN: an international online survey to assess satisfaction with injection experience of patients with neuroendocrine tumours (NETs) enrolled in lanreotide autogel (LAN) patient support programmes (PSPs). J Neuroendocrinol. 2022;34:176–86.
Debon R, Coleone JD, Bellei EA, De Marchi ACB. Mobile health applications for chronic diseases: a systematic review of features for lifestyle improvement. Diabetes Metab Syndr. 2019;13:2507–12.
doi: 10.1016/j.dsx.2019.07.016
pubmed: 31405669